Assessing the inclusion of postinflammatory hyperpigmentation outcomes in acne vulgaris clinical trials

Alyssa Swearingen; Christine Olagun-Samuel; Arielle R Nagler; Prince Adotama

doi:10.1016/j.jaad.2024.10.004

Assessing the inclusion of postinflammatory hyperpigmentation outcomes in acne vulgaris clinical trials

J Am Acad Dermatol. 2024 Oct 10:S0190-9622(24)02962-1. doi: 10.1016/j.jaad.2024.10.004. Online ahead of print.

Authors

Alyssa Swearingen¹, Christine Olagun-Samuel², Arielle R Nagler², Prince Adotama³

Affiliations

¹ Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York; Rutgers New Jersey Medical School, Newark, New Jersey.
² Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York.
³ Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York. Electronic address: Prince.Adotama@nyulangone.org.

PMID: 39393546
DOI: 10.1016/j.jaad.2024.10.004

No abstract available

Keywords: acne vulgaris; acne-induced hyperpigmentation; clinical trials; outcome measures; postinflammatory hyperpigmentation; primary outcomes; secondary outcomes; skin of color.